Name: 6th Annual MarketsandMarkets Real-World Evidence and Life Sciences Analytics Conference
Start: 2023-10-16
End: 2023-10-17
Location: Hampton Inn by Hilton Boston Seaport District

WHAT TO EXPECT

Regulatory view around data quality & data standards.
Leveraging RWE for improving market access.
The adoption & role of AI & ML in clinical trials.
Real-world evidence & Digital Health - The expanded role of RWE for digital health.
Panel Discussion on lessons learned from the recent results of the FDA’s
pilot program RCT DUPLICATE.
Real-World Data & Advanced Analytics.
RWE to inform decision making process in rare diseases where there is lack of evidence.

Learn about the recent trends and advancements in Real-World Evidence Generation
Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators and solution providers

From pharmaceutical and Biopharmaceutical companies

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists within the following departments-

Real-World Evidence, Real-World Data, Health Economics & Outcomes Research- HEOR, Market Access/Value Access, Clinical Outcomes, Clinical Development & research, Clinical trial and others

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note by MarketsandMarkets	08:50 - 08:55
Opening remarks by the Chairperson Pamela Vo, Global HEOR & Access Evidence Lead, Executive Director, Neuroscience, Novartis	08:55 - 09:00
Keynote Presentation: Rising Above the Noise: Basing Drug Price on Drug Value Charles Makin , Head of RWE, Boehringer-Ingelheim	09:00 - 09:30
Leveraging Real World Data to Mitigate Safety Risks William Blumentals, Sr. Director, Head of Pharmacoepidemiology in Specialty Care, Sanofi	09:30 - 10:00
Hybrid Claims Data and Opportunities for Real-World Evidence (RWE) Generation Seth Kuranz, RWE Principal at Forian, Forian Inc	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:10
Use and Accuracy of Privacy Preserving Record Linkage in Clinical Studies Sarah Willis, Director, Vaccines RWE Scientist, Pfizer	11:10 - 11:40
Beyond the Surface: Clinically-Enhanced Claims Data for RWE Generation Jane Huang, Director, Research Consulting, Komodo Health	11:40 - 12:10
Role of patients and caregivers in value framework Anju Parthan, Independent Consultant,	12:10 - 12:40
The Future of Registries & RWE: Accelerating and Innovating with Study Automation, Outcomes-Enriched Linked Data, and Artificial Intelligence Richard Gliklich, Chief Executive Officer, OM1 Inc	12:40 - 13:10
Lunch and Poster Presentation \| One-to-One Networking	13:10 - 14:10
Driving Innovation in the Pharma with Real-World Data Janel Titus, Real-World Data Engagement Lead, Takeda Julia Zhu, Data Sciences Lead, Takeda	14:10 - 14:45
Finding Value in Linking Real-World Data with Social Determinants of Health Pamela Landsman-Blumberg, Senior Vice President - Real-World Evidence and HEOR Insights, Magnolia Market Access	14:45 - 15:15
Panel Discussion – Creating Value from Next Generation RWE Sricharan Bandhakavi, Associate Director, Data Scientist, Alnylam Pharmaceuticals Pamela Landsman-Blumberg, Senior Vice President - Real-World Evidence and HEOR Insights, Magnolia Market Access Danielle Bargo, Director, Global Oncology Real World Data Strategy, AstraZeneca	15:15 - 15:55
Evening Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:55 - 16:35
Enabling in-depth Real-World Evidence through multi-source Real-World Data Todd Somsel, Vice President, Commercial Lead, Real-World Data Marketplace, Prognos Health	16:35 - 17:05
Taking Data Quality to the Next Dimension: Approaches to Oncology Real-World Data (RWD) Brett Wittmershaus, Senior Representative, Flatiron Health	17:05 - 17:35
Closing remarks by the Chairperson Pamela Vo, Global HEOR & Access Evidence Lead, Executive Director, Neuroscience, Novartis	17:35 - 17:35
END OF DAY 1 \| Drinks Reception and Networking	17:35 - 17:35

Registration	08:15 - 08:50
Welcome note by MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman	08:55 - 09:00
Keynote Presentation - Challenges and Solutions to Longitudinal Data Capture in Rare Disease Kristen Ricchetti-Masterson, Senior Director of Real World Evidence, Sarepta Therapeutics	09:00 - 09:30
The use of External Controls and Real-world Evidence to support Clinical Trials for FDA Regulatory Decision Making Megan Sutton, Senior Medical Director, Clinical Development and Real-world Evidence, Lexeo Therapeutics	09:30 - 10:00
Unlocking New Evidence Generation Opportunities with Near-Real-Time EHR Data Conor Wyand, Senior Director, Life Science Solutions, Truveta	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Machine Learning with Real World Data: Opportunities and Practical Considerations Genevieve Lyons, Associate Director, Global HEOR Analytics Alexion, AstraZeneca RDU	11:15 - 11:45
Using AI and ML to Understand Rare Diseases Ryan Rumantir, Principal, Data & Analytics, Eversana	11:45 - 12:15
The Future of Real World Data in Europe Danielle Bargo, Director, Global Oncology Real World Data Strategy, AstraZeneca	12:15 - 12:45
Machine Learning Approaches to Reduce Time to Diagnosis and Treatment for Rare Disease Sricharan Bandhakavi, Associate Director, Data Scientist, Alnylam Pharmaceuticals Charlotte Chen, Director, Commercial Data Science, Alnylam Pharmaceuticals	12:45 - 13:15
Closing remarks by the chairperson	13:15 - 13:20
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:20 - 13:20
End of Conference	13:20 - 13:20